US Patent No: 5,516,637
Number of patents in Portfolio can not be more than 2000
Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
Stats
-
May 14, 1996
Issued date -
Jun 10, 1994
filing date -
08/258,026
serial no -
Expired
status
Importance
Loading Importance Indicators...
Overall
|
US Family Size
|
International Coverage
|
Patent Longevity
|
Forward Citations
|
Abstract
The present invention relates to a fusion protein, comprising a pilin protein or a portion thereof and a heterologous polypeptide (target protein). In a preferred embodiment it relates to a method for displaying the target protein on the outer surface of a bacterial host cell capable of forming pilus. In certain embodiments, it is desirable that the pilus is a receptor for bacteriophage attachment and infection. The F pilus is preferred.
Loading the Abstract Image...
First Claim
Related Publications
Loading Related Publications...
- 15 United States
- 10 France
- 8 Japan
- 7 China
- 5 Korea
- 2 Other
Patent Owner(s)
| Patent Owner | Address | Total Patents |
|---|---|---|
| DADE BEHRING INC. | DEERFIELD, IL | 161 |
International Classification(s)
Inventor(s)
| Inventor Name | Address | # of filed Patents | Total Citations |
|---|---|---|---|
| Huang, Grace P | Miami, FL | 1 | 77 |
| Rhode, Peter R | Miami, FL | 13 | 138 |
| Stinson, Jeffrey R | Brookeville, MD | 30 | 195 |
| Wong, Hing C | Weston, FL | 72 | 326 |
Cited Art Landscape
| Patent Info | (Count) | # Cites | Year |
|---|---|---|---|
|
|
|||
| 5,223,409 Directed evolution of novel binding proteins | 947 | 1991 | |
|
|
|||
| 5,348,867 Expression of proteins on bacterial surface | 56 | 1991 | |
Patent Citation Ranking
Forward Cite Landscape
| Patent Info | (Count) | # Cites | Year |
|---|---|---|---|
|
|
|||
| 7,700,739 IL-12/p40 binding proteins | 1 | 2006 | |
| 7,612,181 Dual variable domain immunoglobulin and uses thereof | 18 | 2006 | |
| 8,497,072 Amyloid-beta globulomer antibodies | 0 | 2006 | |
| 7,915,388 Interleukin-13 binding proteins | 0 | 2007 | |
| 8,455,626 Aβ conformer selective anti-aβ globulomer monoclonal antibodies | 0 | 2007 | |
| 8,323,651 Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof | 0 | 2009 | |
| 8,258,268 Dual variable domain immunoglobulin and uses thereof | 3 | 2009 | |
| 8,383,778 IL-1 binding proteins | 0 | 2010 | |
| 8,420,083 Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof | 0 | 2010 | |
|
|
|||
| 7,785,829 Nogo receptor binding protein | 3 | 2004 | |
| 8,486,893 Treatment of conditions involving demyelination | 0 | 2005 | |
| 8,551,476 SP35 antibodies and uses thereof | 0 | 2007 | |
| 8,128,926 Sp35 antibodies and uses thereof | 3 | 2009 | |
| 8,058,406 Composition comprising antibodies to LINGO or fragments thereof | 3 | 2009 | |
| 8,425,910 Composition comprising antibodies to LINGO or fragments thereof | 0 | 2011 | |
|
|
|||
| 7,736,635 Branched molecular scaffolds for linking polymer residues to biologically active moieties | 0 | 2004 | |
| 8,129,505 Comb polymers | 0 | 2006 | |
| 8,075,889 Antibody molecules having specificity for human IL-6 | 0 | 2006 | |
| 7,931,900 Method for the treatment of multiple sclerosis by inhibiting IL-17 activity | 0 | 2008 | |
| 8,486,662 DNA encoding antibody molecules having specificity for human IL-6 | 0 | 2011 | |
| 8,580,265 Antibody molecules which bind IL-17A and IL-17F | 0 | 2012 | |
|
|
|||
| 8,211,430 Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions | 1 | 2006 | |
| 7,393,919 Peptides, derivatives and analogs thereof, and methods of using same | 5 | 2006 | |
| 7,714,103 Peptides, derivatives and analogs thereof, and methods of using same | 3 | 2008 | |
| 7,989,415 Peptides, derivatives and analogs thereof, and methods of using same | 2 | 2009 | |
| 8,383,578 Peptides, derivatives and analogs thereof, and methods of using same | 0 | 2011 | |
|
|
|||
| 7,429,646 Antibodies to human tumor necrosis factor receptor-like 2 | 2 | 2000 | |
| 7,597,886 Tumor necrosis factor-gamma | 3 | 2001 | |
| 7,820,798 Tumor necrosis factor-gamma | 0 | 2007 | |
| 7,824,675 Use of an antibody that binds human tumor necrosis factor receptor-like 2 | 0 | 2008 | |
| 8,093,363 Tumor necrosis factor-gamma | 0 | 2010 | |
|
|
|||
| 7,582,461 Kinase and phosphatase assays | 3 | 2004 | |
| 7,619,059 Bimolecular optical probes | 0 | 2004 | |
| 7,727,752 Kinase and phosphatase assays | 2 | 2006 | |
| 8,067,536 Kinase and phosphatase assays | 1 | 2010 | |
|
|
|||
| 6,994,982 Isolating biological modulators from biodiverse gene fragment libraries | 1 | 2000 | |
| 7,270,969 Methods of constructing and screening diverse expression libraries | 5 | 2003 | |
| 7,803,765 Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom | 1 | 2004 | |
| 8,575,070 Methods of constructing and screening libraries of peptide structures | 0 | 2007 | |
|
|
|||
| 7,563,882 Polynucleotides encoding antibodies that bind to the C35 polypeptide | 16 | 2003 | |
| 7,750,125 Antibodies that bind to the C35 polypeptide | 11 | 2007 | |
| 7,968,688 Antibodies that bind to the C35 polypeptide | 0 | 2009 | |
| 7,879,990 Polynucleotides encoding antibodies that bind to the C35 polypeptide | 0 | 2009 | |
|
|
|||
| 7,101,549 Glycoprotein VI and uses thereof | 4 | 2004 | |
| 7,597,888 Glycoprotein VI and uses thereof | 3 | 2006 | |
| 8,137,923 Glycoprotein VI and uses thereof | 0 | 2010 | |
|
|
|||
| 7,393,534 Compositions and methods for immunotherapy of cancer and infectious diseases | 0 | 2004 | |
| 8,257,714 Compositions and methods for immunotherapy of cancer and infectious diseases | 0 | 2008 | |
|
|
|||
| 7,259,002 Polynucleotide encoding a novel acyl coenzyme A, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof | 0 | 2004 | |
| 7,482,124 Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema | 0 | 2006 | |
|
|
|||
| 7,427,469 Method of treating cytomegalovirus with DC-SIGN blockers | 2 | 2003 | |
| 7,419,789 Method of inhibiting binding of Dengue virus to a human cell with DC-SIGN blockers | 0 | 2003 | |
|
|
|||
| 8,460,667 EPHA2 receptor antagonist antibodies | 0 | 2007 | |
| 8,153,765 Anti-CD38 antibodies for the treatment of cancer | 0 | 2007 | |
|
|
|||
| 7,297,762 Modified avian pancreatic polypeptide miniature binding proteins | 0 | 2001 | |
| 7,495,070 Protein binding miniature proteins | 0 | 2004 | |
|
|
|||
| 8,114,606 ARL-1 specific antibodies | 0 | 2008 | |
|
|
|||
| 8,318,905 Antibodies for depletion of ICOS-positive cells in vivo | 0 | 2005 | |
|
|
|||
| 7,125,679 Methods to screen peptide libraries using minicell display | 7 | 2002 | |
|
|
|||
| 8,231,878 Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof | 0 | 2009 | |
|
|
|||
| 8,568,719 Antibodies against human respiratory syncytial virus (RSV) and methods of use | 0 | 2010 | |
|
|
|||
| 6,040,136 Enrichment method for variant proteins with altered binding properties | 20 | 1997 | |
|
|
|||
| 7,355,015 Matriptase, a serine protease and its applications | 2 | 2000 | |
|
|
|||
| 7,885,449 System for detecting infectious agents using computer-controlled automated image analysis | 0 | 2008 | |
|
|
|||
| 5,922,537 Nanoparticles biosensor | 168 | 1996 | |
|
|
|||
| 7,041,441 Phage display of intact domains at high copy number | 0 | 1997 | |
|
|
|||
| 7,060,462 AopB gene, protein,homologs, fragments and variants thereof, and their use for cell surface display | 1 | 2001 | |
|
|
|||
| 5,981,249 Single-chain polypeptides comprising creatine kinase M and creatine kinase B | 0 | 1998 | |
|
|
|||
| 6,165,722 Representations of bimolecular interactions | 5 | 1999 | |
|
|
|||
| 6,867,189 Use of adipsin/complement factor D in the treatment of metabolic related disorders | 5 | 2002 | |
|
|
|||
| 7,732,159 Assays for cancer patient monitoring based on levels of analyte components of the plasminogen activator system in body fluid samples | 0 | 2007 | |
|
|
|||
| 6,475,785 Single-chain polypeptides comprising troponin I N-terminal fragments and troponin C | 2 | 1999 | |
|
|
|||
| 7,294,701 Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same | 2 | 2003 | |
|
|
|||
| 7,611,858 Detection of cannabinoid receptor biomarkers and uses thereof | 0 | 2007 | |
|
|
|||
| 7,807,168 Selection of human TNFα specific antibodies | 0 | 2008 | |
|
|
|||
| 6,479,280 Recombinant phages capable of entering host cells via specific interaction with an artificial receptor | 3 | 1999 | |
|
|
|||
| 8,586,714 Dual variable domain immunoglobulins and uses thereof | 0 | 2010 | |
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|
| Fee | Large entity fee | small entity fee | micro entity fee |
|---|---|---|---|
| Surcharge after expiration - Late payment is unavoidable | $700.00 | $350.00 | $175.00 |
| Surcharge after expiration - Late payment is unintentional | $1,640.00 | $820.00 | $410.00 |